PMID- 25650873
OWN - NLM
STAT- MEDLINE
DCOM- 20160505
LR  - 20150813
IS  - 1478-3231 (Electronic)
IS  - 1478-3223 (Linking)
VI  - 35
IP  - 9
DP  - 2015 Sep
TI  - Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic 
      HIV/HCV genotype 1-coinfected patients.
PG  - 2090-9
LID - 10.1111/liv.12799 [doi]
AB  - BACKGROUND & AIMS: The efficacy and safety of triple therapy combining boceprevir 
      (BOC) or telaprevir (TVR) with pegylated interferon-alfa and ribavirin 
      (PegIFN/RBV) has rarely been investigated in human immunodeficiency 
      virus/hepatitis C virus (HIV/HCV) genotype 1-coinfected patients with cirrhosis. 
      METHODS: We conducted a European (France, Italy, Germany, Netherlands) 
      multicentre study of triple therapy in cirrhotic HIV/HCV GT1-coinfected patients. 
      RESULTS: Fifty-nine patients (47 TVR, 12 BOC) were studied. Median CD4 cell count 
      was 457 (293-578)/mm(3), and HIV viral load was <50 copies/ml in 93% of patients. 
      The HCV genotype was GT1a (78%) or GT1b (13%). Previous PegIFN/RBV therapy had 
      resulted in non-response (73%) or relapse (12%), and 15% of patients were 
      treatment-naive. The sustained virological response rate at week 12 (SVR12) was 
      53% overall (57% with TVR, 36% with BOC). A baseline HCV-RNA level <800 000 IU/ml 
      tended to be associated with SVR12 (65 vs 42%, P = 0.11). In multivariate 
      analysis, a virological response at week 4 after BOC or TVR initiation was 
      significantly associated with SVR12 (P = 0.040). Early discontinuation of triple 
      therapy was frequent (n = 26, 44%), because of non-response/breakthrough (65%) or 
      adverse events (AEs) (35%). Three patients died. Severe anaemia (<9 g/dl) 
      occurred in 14 patients (25%), leading to RBV dose reduction (22%), 
      erythropoietin use (56%) or blood transfusion (14%). In multivariate analysis, 
      lack of RBV dose reduction was significantly associated with severe AEs (P = 
      0.006). CONCLUSIONS: More than half of HIV/HCV GT1-coinfected patients with 
      cirrhosis achieved a SVR12. To avoid unnecessary adverse effects, therapy should 
      be discontinued if no response is obtained at week 4.
CI  - (c) 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Miailhes, Patrick
AU  - Miailhes P
AD  - Department of Infectious and Tropical Diseases, Croix Rousse Hospital, Hospices 
      Civils de Lyon, Lyon, France.
FAU - Gilbert, Camille
AU  - Gilbert C
AD  - Centre INSERM U897-Epidemiologie-Biostatistique, INSERM, ISPED, Bordeaux, France.
FAU - Lacombe, Karine
AU  - Lacombe K
AD  - Sorbonne Universites, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis 
      d'Epidemiologie et de Sante Publique, Paris, France.
AD  - Department of Infectious and Tropical Diseases, Saint-Antoine Hospital, AP-HP, 
      Paris, France.
FAU - Arends, Joop E
AU  - Arends JE
AD  - Department of Internal Medicine and Infectious Diseases, University Medical 
      Center Utrecht (UMCU), Utrecht, the Netherlands.
FAU - Puoti, Massimo
AU  - Puoti M
AD  - Infectious Diseases Department, AO Niguarda Ca' Granda, Milano, Italy.
FAU - Rockstroh, Jurgen K
AU  - Rockstroh JK
AD  - Infectious Diseases Department, University of Bonn, Bonn, Germany.
FAU - Sogni, Philippe
AU  - Sogni P
AD  - Hepatology Unit, Cochin Hospital, AP-HP, Paris, France.
AD  - Paris and Cochin Institute, INSERM-U1016, Paris-Descartes University, Paris, 
      France.
FAU - Fontaine, Helene
AU  - Fontaine H
AD  - Hepatology Unit, Cochin Hospital, AP-HP, Paris, France.
AD  - Paris and Cochin Institute, INSERM-U1016, Paris-Descartes University, Paris, 
      France.
FAU - Rosenthal, Eric
AU  - Rosenthal E
AD  - Department of Internal Medicine, CHU de Nice, Archet Hospital, University of Nice 
      Sophia Antipolis, Nice, France.
FAU - Winnock, Maria
AU  - Winnock M
AD  - Centre INSERM U897-Epidemiologie-Biostatistique, INSERM, ISPED, Bordeaux, France.
FAU - Loko, Marc-Arthur
AU  - Loko MA
AD  - Centre INSERM U897-Epidemiologie-Biostatistique, INSERM, ISPED, Bordeaux, France.
FAU - Wittkop, Linda
AU  - Wittkop L
AD  - Centre INSERM U897-Epidemiologie-Biostatistique, INSERM, ISPED, Bordeaux, France.
AD  - CHU de Bordeaux, Pole de Sante Publique, Service d'Information Medicale, 
      Bordeaux, France.
FAU - Dabis, Francois
AU  - Dabis F
AD  - Centre INSERM U897-Epidemiologie-Biostatistique, INSERM, ISPED, Bordeaux, France.
AD  - CHU de Bordeaux, Pole de Sante Publique, Service d'Information Medicale, 
      Bordeaux, France.
FAU - Salmon, Dominique
AU  - Salmon D
AD  - Department of Internal Medicine and Infectious Diseases, Cochin Hospital, Paris 
      Descartes University, AP-HP, Paris, France.
CN  - ESCMID European Study Group on Viral Hepatitis
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150223
PL  - United States
TA  - Liver Int
JT  - Liver international : official journal of the International Association for the 
      Study of the Liver
JID - 101160857
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon-alpha)
RN  - 0 (Oligopeptides)
RN  - 0 (RNA, Viral)
RN  - 49717AWG6K (Ribavirin)
RN  - 655M5O3W0U (telaprevir)
RN  - 89BT58KELH 
      (N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide)
RN  - 9DLQ4CIU6V (Proline)
SB  - IM
MH  - Anemia
MH  - Antiviral Agents/therapeutic use
MH  - Cohort Studies
MH  - Coinfection/drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - France
MH  - Genotype
MH  - Germany
MH  - HIV Infections/*drug therapy
MH  - Hepacivirus/*genetics
MH  - Hepatitis C, Chronic/*drug therapy
MH  - Humans
MH  - Interferon-alpha/therapeutic use
MH  - Italy
MH  - Liver Cirrhosis/*complications
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Oligopeptides/*therapeutic use
MH  - Proline/*analogs & derivatives/therapeutic use
MH  - RNA, Viral/blood
MH  - Ribavirin/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - HIV/HCV genotype 1 coinfection
OT  - boceprevir
OT  - cirrhosis
OT  - telaprevir
EDAT- 2015/02/05 06:00
MHDA- 2016/05/06 06:00
CRDT- 2015/02/05 06:00
PHST- 2014/08/22 00:00 [received]
PHST- 2015/01/30 00:00 [accepted]
PHST- 2015/02/05 06:00 [entrez]
PHST- 2015/02/05 06:00 [pubmed]
PHST- 2016/05/06 06:00 [medline]
AID - 10.1111/liv.12799 [doi]
PST - ppublish
SO  - Liver Int. 2015 Sep;35(9):2090-9. doi: 10.1111/liv.12799. Epub 2015 Feb 23.